Form 4: Kymera Therapeutics Director Gorjan Hrustanovic Granted 16,000 Stock Options

Kymera Therapeutics, Inc. director Gorjan Hrustanovic was granted 16,000 stock options with an exercise price of $46.47, vesting fully by June 25, 2026, or the next annual meeting.

Summary

• Gorjan Hrustanovic, a Director of Kymera Therapeutics, Inc. (KYMR), was granted 16,000 stock options.
• The transaction date for this grant is June 25, 2025.
• Each option has an exercise price of $46.47.
• The options become exercisable on June 25, 2025, and are set to expire on June 24, 2035.
• The shares underlying these options will vest in full upon the earlier of June 25, 2026, or the date of the Issuer's next annual meeting of stockholders.
• Mr. Hrustanovic, as a member of BVF Partners L.P., is obligated to transfer any economic benefit from the sale of shares from these options to BVF and disclaims beneficial ownership except for his pecuniary interest.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is generally a positive sign of alignment and retention, though it's a routine compensation event rather than a major strategic announcement.

Positives

• The grant of stock options to a director aligns the director's interests with those of shareholders, incentivizing long-term performance.
• The options have a 10-year expiration period, providing a long-term incentive for the director.

Negatives

• The exercise price of $46.47 is the current market price at the time of grant, meaning the options only have value if the stock price increases above this level.

Risks

• The value of the stock options is entirely dependent on the future performance of Kymera Therapeutics' common stock price.

Future Outlook

The stock option grant provides a long-term incentive for the director, aligning their future financial interests with the company's stock performance over the next decade.

Management Comments

• The reporting person, Gorjan Hrustanovic, disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any, due to his obligation to transfer economic benefit to BVF Partners L.P.

Industry Context

This is a standard equity compensation practice in the biotechnology and pharmaceutical industries, commonly used to attract and retain experienced directors and align their interests with long-term company growth and shareholder value creation.

Corporate Governance

Related Party Transactions

• Gorjan Hrustanovic, as a member of BVF Partners L.P., is obligated to transfer the economic benefit, if any, received upon the sale of shares issuable upon exercise of the equity grants to BVF.

Stakeholder Impact

• Shareholders: Potential positive impact through improved director alignment with long-term company performance and value creation.

Next Steps

• The shares underlying the stock options will vest in full upon the earlier of June 25, 2026, or the date of the next annual meeting of the Issuer's stockholders.

Key Dates

Recommendation

Keywords

Kymera Therapeutics, KYMR, Stock Options, Director Compensation, SEC Form 4, Insider Trading, Equity Grant, Corporate Governance, Biotechnology, Pharmaceuticals